{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:14:54Z","timestamp":1773191694726,"version":"3.50.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2531,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Catherine Heather Patron Bequest"},{"name":"University of Sydney Compacts Grant"},{"name":"Catherine Heather Patron Bequest"},{"name":"University of Sydney Compacts Grant"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effects of synthetic brain natriuretic peptide (BNP1-32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the cardiorenal and endocrine effects of SC administered synthetic canine BNP1-32, with or without furosemide, in dogs with CHF caused by myxomatous mitral valve disease (MMVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seven client-owned male dogs with compensated American College of Veterinary Internal Medicine stage C CHF caused by MMVD on chronic treatment with furosemide, benazepril, and pimobendan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-dose, crossover, pilot study. Each dog received a dose of BNP1-32 (5\u2009\u03bcg\/kg), furosemide (2\u2009mg\/kg), and both BNP1-32\/furosemide (5\u2009\u03bcg\/kg and 2\u2009mg\/kg, respectively) SC with a 2-week washout period among each treatment. Between- and within-treatment effects were evaluated using linear mixed modeling with restricted maximum likelihood estimation and evaluation of least square differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rapid absorption of BNP1-32 and a corresponding rise in urinary cyclic guanosine monophosphate excretion was observed at 1-2\u2009hours after any treatment containing BNP1-32 (P &amp;lt;\u2009.05). However, BNP1-32 did not influence measured cardiorenal variables. Plasma aldosterone concentrations were below quantifiable levels in majority of the samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>No beneficial cardiorenal effects were detected. It is possible that dogs with chronic CHF have a reduction in natriuretic peptide responsiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15416","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T13:55:21Z","timestamp":1548942921000},"page":"462-470","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-3029","authenticated-orcid":false,"given":"Mariko","family":"Yata","sequence":"first","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, University of Sydney , Sydney, New South Wales,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans S.","family":"Kooistra","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine, Utrecht University Department of Clinical Sciences of Companion Animals, , Utrecht,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niek J.","family":"Beijerink","sequence":"additional","affiliation":[{"name":"Sydney School of Veterinary Science, Faculty of Science, University of Sydney , Sydney, New South Wales,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,1]]},"reference":[{"key":"2026020922220685800_jvim15416-bib-0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jvc.2012.01.011","article-title":"Historical review, epidemiology and natural history of degenerative mitral valve disease","volume":"14","author":"Borgarelli","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0002","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1939-1676.2009.0392.x","article-title":"Guidelines for the diagnosis and treatment of canine chronic valvular heart disease","volume":"23","author":"Atkins","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0004","first-page":"1219","article-title":"Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases","volume":"52","author":"De Madron","year":"2011","journal-title":"Can Vet J"},{"key":"2026020922220685800_jvim15416-bib-0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5326\/0420249","article-title":"Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs","volume":"42","author":"Lombard","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020922220685800_jvim15416-bib-0006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2007.0008.x","article-title":"Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease","volume":"22","author":"Borgarelli","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0007","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2885.2009.01122.x","article-title":"Aldosterone receptor antagonists \u2013 how cardiovascular actions may explain their beneficial effects in heart failure","volume":"33","author":"Ovaert","year":"2010","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922220685800_jvim15416-bib-0009","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jvc.2012.01.003","article-title":"Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease","volume":"14","author":"Peddle","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0010","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/jvim.14841","article-title":"Short-term efficacy and safety of torasemide and furosemide in 366 dogs with degenerative mitral valve disease: the TEST study","volume":"31","author":"Chetboul","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jvc.2012.01.004","article-title":"Mitral valve repair in dogs","volume":"14","author":"Uechi","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0012","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2460\/javma.240.10.1194","article-title":"Mitral valve repair under cardiopulmonary bypass in small-breed dogs: 48 cases (2006\u20132009)","volume":"240","author":"Uechi","year":"2012","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922220685800_jvim15416-bib-0013","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1748-5827.2012.01305.x","article-title":"Long-term outcome in dogs undergoing mitral valve repair with suture annuloplasty and chordae tendinae replacement","volume":"54","author":"Mizuno","year":"2013","journal-title":"J Small Anim Pract"},{"key":"2026020922220685800_jvim15416-bib-0014","doi-asserted-by":"crossref","first-page":"R1077","DOI":"10.1152\/ajpregu.1997.272.4.R1077","article-title":"BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure","volume":"272","author":"Grantham","year":"1997","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026020922220685800_jvim15416-bib-0015","first-page":"H2406","article-title":"Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart","volume":"273","author":"Yamamoto","year":"1997","journal-title":"Am J Physiol"},{"key":"2026020922220685800_jvim15416-bib-0016","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0735-1097(00)00911-6","article-title":"Subcutaneous administration of brain natriuretic peptide in experimental heart failure","volume":"36","author":"Chen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0017","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.0000124064.00494.21","article-title":"Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure","volume":"109","author":"Cataliotti","year":"2004","journal-title":"Circulation"},{"key":"2026020922220685800_jvim15416-bib-0018","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ejheart.2005.12.005","article-title":"Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure","volume":"8","author":"Chen","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"2026020922220685800_jvim15416-bib-0019","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jacc.2006.08.066","article-title":"Acute pohosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart","volume":"49","author":"Forfia","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/heartjnl-2013-305167","article-title":"\u03b2-Adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure?","volume":"100","author":"Thireau","year":"2014","journal-title":"Heart"},{"key":"2026020922220685800_jvim15416-bib-0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous Nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"2026020922220685800_jvim15416-bib-0022","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Publication Committee for the VMAC Investigators","year":"2002","journal-title":"J Am Med Assoc"},{"key":"2026020922220685800_jvim15416-bib-0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cardfail.2003.08.011","article-title":"Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure","volume":"10","author":"Chen","year":"2004","journal-title":"J Card Fail"},{"key":"2026020922220685800_jvim15416-bib-0024","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jacc.2012.07.056","article-title":"Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020922220685800_jvim15416-bib-0026","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1681\/ASN.2006020161","article-title":"Maximizing the renal cyclic 3\u2032-5\u2032-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure","volume":"17","author":"Chen","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026020922220685800_jvim15416-bib-0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jvc.2017.02.003","article-title":"Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease","volume":"19","author":"Oyama","year":"2017","journal-title":"J Vet Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0028","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ejhf.468","article-title":"Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure","volume":"18","author":"McKie","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026020922220685800_jvim15416-bib-0029","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/cs0880159","article-title":"Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects","volume":"88","author":"Clarkson","year":"1995","journal-title":"Clin Sci"},{"key":"2026020922220685800_jvim15416-bib-0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCHEARTFAILURE.108.790774","article-title":"Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure","volume":"1","author":"Niederkofler","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026020922220685800_jvim15416-bib-0031","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jchromb.2008.12.063","article-title":"Development and validation of an LC\u2013MS\/MS method for quantification of cyclic guanosine 3\u2032,5\u2032-monophosphate (cGMP) in clinical applications: a comparison with a EIA method","volume":"877","author":"Zhang","year":"2009","journal-title":"J Chromatogr B"},{"key":"2026020922220685800_jvim15416-bib-0032","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/clinchem\/37.2.186","article-title":"Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac diseases","volume":"37","author":"Vorderwinkler","year":"1991","journal-title":"Clin Chem"},{"key":"2026020922220685800_jvim15416-bib-0033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2125.2003.01888.x","article-title":"Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects","volume":"56","author":"W-c","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2026020922220685800_jvim15416-bib-0034","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tvjl.2007.07.002","article-title":"Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog","volume":"178","author":"Schellenberg","year":"2008","journal-title":"Vet J"},{"key":"2026020922220685800_jvim15416-bib-0035","doi-asserted-by":"crossref","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2026020922220685800_jvim15416-bib-0036","doi-asserted-by":"crossref","first-page":"R897","DOI":"10.1152\/ajpregu.00569.2006","article-title":"Des-serine-proline brain natriuretic peptide 3\u201332 in cardiorenal regulation","volume":"292","author":"Boerrigter","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026020922220685800_jvim15416-bib-0037","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1042\/cs0960005","article-title":"Renal effects of brain natriuretic peptide in patients with congestive heart failure","volume":"96","author":"Jensen","year":"1999","journal-title":"Clin Sci"},{"key":"2026020922220685800_jvim15416-bib-0038","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0002-8703(98)70316-3","article-title":"Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure","volume":"135","author":"Nakamura","year":"1998","journal-title":"Am Heart J"},{"key":"2026020922220685800_jvim15416-bib-0039","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-2999(89)90321-X","article-title":"Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta","volume":"174","author":"Stasch","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"2026020922220685800_jvim15416-bib-0040","doi-asserted-by":"crossref","first-page":"F1220","DOI":"10.1152\/ajprenal.1988.255.6.F1220","article-title":"Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor","volume":"255","author":"Wong","year":"1988","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026020922220685800_jvim15416-bib-0041","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"2026020922220685800_jvim15416-bib-0042","doi-asserted-by":"crossref","first-page":"F1047","DOI":"10.1152\/ajprenal.00164.2014","article-title":"ANP-induced signaling cascade and its implications in renal pathophysiology","volume":"308","author":"Theilig","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026020922220685800_jvim15416-bib-0043","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11010-009-0326-8","article-title":"Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome","volume":"334","author":"Martel","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"2026020922220685800_jvim15416-bib-0044","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0735-1097(00)00790-7","article-title":"Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure","volume":"36","author":"Katz","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026020922220685800_jvim15416-bib-0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"},{"key":"2026020922220685800_jvim15416-bib-0046","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study","volume":"4","author":"Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026020922220685800_jvim15416-bib-0047","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2460\/ajvr.1997.58.01.77","article-title":"Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs","volume":"58","author":"H\u00e4ggstr\u00f6m","year":"1997","journal-title":"Am J Vet Res"},{"key":"2026020922220685800_jvim15416-bib-0048","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/jvim.12217","article-title":"Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure","volume":"27","author":"H\u00e4ggstr\u00f6m","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020922220685800_jvim15416-bib-0049","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2460\/ajvr.73.11.1765","article-title":"Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease","volume":"73","author":"Hezzell","year":"2012","journal-title":"Am J Vet Res"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/462\/66659100\/jvim15416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/33\/2\/462\/66659100\/jvim15416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:31:07Z","timestamp":1770694267000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/33\/2\/462\/8448047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15416","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2019,3,1]]},"assertion":[{"value":"2018-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}